BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sommer CM, Kauczor HU, Pereira PL. Locoregional Therapies of Cholangiocarcinoma. Visc Med 2016;32:414-20. [PMID: 28229076 DOI: 10.1159/000453010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Li F, Jiang Y, Jiang L, Li Q, Yan X, Huang S, Chen J, Yuan S, Fu Y, Liu J. Effect of lymph node resection on prognosis of resectable intrahepatic cholangiocarcinoma: A systematic review and meta-analysis. Front Oncol 2022;12:957792. [DOI: 10.3389/fonc.2022.957792] [Reference Citation Analysis]
2 Hosseini Shabanan S, Nezami N, Abdelsalam ME, Sheth RA, Odisio BC, Mahvash A, Habibollahi P. Selective Internal Radiation Therapy with Yttrium-90 for Intrahepatic Cholangiocarcinoma: A Systematic Review on Post-Treatment Dosimetry and Concomitant Chemotherapy. Current Oncology 2022;29:3825-48. [DOI: 10.3390/curroncol29060306] [Reference Citation Analysis]
3 Bekki Y, Von Ahrens D, Takahashi H, Schwartz M, Gunasekaran G. Recurrent Intrahepatic Cholangiocarcinoma - Review. Front Oncol 2021;11:776863. [PMID: 34746017 DOI: 10.3389/fonc.2021.776863] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Rizzo A, Ricci AD, Brandi G. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? Cancer Treat Res Commun 2021;27:100356. [PMID: 33799004 DOI: 10.1016/j.ctarc.2021.100356] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
5 Zhao Q, Chen Y, Du S, Yang X, Chen Y, Ji Y, Zeng Z. Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases. Cancer Biol Ther 2021;22:175-83. [PMID: 33722163 DOI: 10.1080/15384047.2020.1834792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Brandi G, Rizzo A, Dall’olio FG, Felicani C, Ercolani G, Cescon M, Frega G, Tavolari S, Palloni A, De Lorenzo S, Abbati F, Mollica V, Ricci AD, Serra C. Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience. International Journal of Hyperthermia 2020;37:479-85. [DOI: 10.1080/02656736.2020.1763484] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 17.0] [Reference Citation Analysis]
7 Belfiore MP, Reginelli A, Maggialetti N, Carbone M, Giovine S, Laporta A, Urraro F, Nardone V, Grassi R, Cappabianca S, Brunese L. Preliminary results in unresectable cholangiocarcinoma treated by CT percutaneous irreversible electroporation: feasibility, safety and efficacy. Med Oncol 2020;37:45. [PMID: 32270353 DOI: 10.1007/s12032-020-01360-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
8 Struecker B, Morguel H, Pascher A. Cholangiokarzinome – aktuelle Therapiestandards. Onkologe 2020;26:238-245. [DOI: 10.1007/s00761-019-00692-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 White SB, Maddirela D. Intrahepatic Cholangiocarcinoma. Image-Guided Interventions in Oncology 2020. [DOI: 10.1007/978-3-030-48767-6_8] [Reference Citation Analysis]
10 Xu C, Li L, Xu W, Du C, Yang L, Tong J, Yi Y. Ultrasound-guided percutaneous microwave ablation versus surgical resection for recurrent intrahepatic cholangiocarcinoma: intermediate-term results. Int J Hyperthermia 2019;36:351-8. [PMID: 30845852 DOI: 10.1080/02656736.2019.1571247] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
11 Jang HH, Park SB, Hong JS, Lee HL, Song YH, Kim J, Jung YH, Kim C, Kim DM, Lee SE, Jeong YI, Kang DH. Piperlongumine-Eluting Gastrointestinal Stent Using Reactive Oxygen Species-Sensitive Nanofiber Mats for Inhibition of Cholangiocarcinoma Cells. Nanoscale Res Lett 2019;14:58. [PMID: 30778693 DOI: 10.1186/s11671-019-2887-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
12 Johnson BW, Wright GP. Regional therapies for the treatment of primary and metastatic hepatic tumors: A disease-based review of techniques and critical appraisal of current evidence. Am J Surg 2019;217:541-5. [PMID: 30782316 DOI: 10.1016/j.amjsurg.2018.10.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
13 Melekhina OV, Kulezneva YV, Efanov MG, Musatov AB. Combined minimally invasive treatment of liver and bile ducts malignancies. Ann hir gepatol 2018;23:26-36. [DOI: 10.16931/1995-5464.2018226-36] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Tautenhahn HM, Brückner S, Rauchfuß F, Donndorf F, Ardelt M, Fahrner R, Tannapfel A, Settmacher U. [Precancerous and early stage cancer of the bile duct system]. Chirurg 2018;89:274-80. [PMID: 29177915 DOI: 10.1007/s00104-017-0553-6] [Reference Citation Analysis]
15 Labib PL, Davidson BR, Sharma RA, Pereira SP. Locoregional therapies in cholangiocarcinoma. Hepat Oncol 2017;4:99-109. [PMID: 29367874 DOI: 10.2217/hep-2017-0014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]